All In Biotech

Drug Trial Radar · NCT01786395

Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa

Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period

Last checked: Nov 20, 2026Latest source record: Jan 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

202

Actual

Start

Mar 2013

Primary completion

Apr 2015

Sponsor

Lead sponsor
R-Tech Ueno, Ltd.Industry
Sponsor type
Industry
First posted
Feb 8, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter trial performed in Japan, consisting of a comparative study period and a continuous administration period. Effect of 0.15% UF-021 eye drops on improvement in central retinal sensitivity with HFA will be verified in 52 weeks comparative study period by a placebo-controlled, double-masked study in patients with retinitis pigmentosa. The safety of same eye drops will also be examined in 52 weeks continuous administration period, in all the patients who completed the comparative study period.

Conditions

  • Retinitis Pigmentosa

Interventions

  • UF-021Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in the value of the mean retinal sensitivity at four central points through HFA (10-2)Time frame: baseline and 1 year

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Nagoya, Aichi-ken, Japan

  • Site not named

    Hirosaki, Aomori, Japan

  • Site not named

    Chiba, Chiba, Japan

  • Site not named

    Matsuyama, Ehime, Japan

  • Site not named

    Fukuoka, Fukuoka, Japan

  • Site not named

    Maebashi, Gunma, Japan

  • Site not named

    Kure, Hiroshima, Japan

  • Site not named

    Sapporo, Hokkaido, Japan

  • Site not named

    Kobe, Hyōgo, Japan

  • Site not named

    Mito, Ibaraki, Japan

  • Site not named

    Morioka, Iwate, Japan

  • Site not named

    Kumamoto, Kumamoto, Japan

  • Site not named

    Kyoto, Kyoto, Japan

  • Site not named

    Tsu, Mie-ken, Japan

  • Site not named

    Sendai, Miyagi, Japan

  • Site not named

    Miyakonojō, Miyazaki, Japan

  • Site not named

    Miyazaki, Miyazaki, Japan

  • Site not named

    Beppu, Oita Prefecture, Japan

  • Site not named

    Okayama, Okayama-ken, Japan

  • Site not named

    Tamano, Okayama-ken, Japan

  • Site not named

    Osaka, Osaka, Japan

  • Site not named

    Sayama, Osaka, Japan

  • Site not named

    Izumo, Shimane, Japan

  • Site not named

    Hamamatsu, Shizuoka, Japan

  • Site not named

    Ohtawara, Tochigi, Japan

  • Site not named

    Tokushima, Tokushima, Japan

  • Site not named

    Bunkyo-ku, Tokyo, Japan

  • Site not named

    Chiyoda-ku, Tokyo, Japan

  • Site not named

    Minato-ku, Tokyo, Japan

  • Site not named

    Mitaka, Tokyo, Japan

  • Site not named

    tabashi City, Tokyo, Japan

  • Site not named

    Toyama, Toyama, Japan

  • Site not named

    Wakayama, Wakayama, Japan

  • Site not named

    Chūō, Yamanashi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.